Peptides DB
Research-centric peptide and protocol reference hub

AHK-Cu (Copper Tripeptide-3) record · updated 17h ago

Skin & aestheticsHealing & recoveryGrade B · human evidenceResearch use only
All 1 studiesJump to the evidenceCompare
What is AHK-Cu (Copper Tripeptide-3) used for?

AHK-Cu (Copper Tripeptide-3) is a synthetic alanine-histidine-lysine peptide bound to copper, studied topically for stimulating dermal papilla cells and supporting hair follicle health.

How it works: Copper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signaling

Primarily researched for · Skin & aestheticsRoute · Topical / subcutaneous

Development stage

where AHK-Cu (Copper Tripeptide-3) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 5 registered trials. It describes the research record, not a recommendation.

Identity
NameAHK-Cu (Copper Tripeptide-3)
Full name
Sequence
ClassSkin
Research levelWell Studied
Discovered byCurated master list · 2026
Pharmacology
MechanismCopper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signaling
RouteTopical / subcutaneous
Half-life
Time to peak
Duration
Extraction confidence0.50
Effect profile · 0–5
Skin & aesthetics: Healing 4.0, Muscle 0.0, Metabolic 0.0, Neuro 0.0, Sleep 0.0, Immune 1.0, Skin 5.0Healing & recovery — 4.0 / 5Inflammation & immune — 1.0 / 5Skin & aesthetics — 5.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin4.00.00.00.00.01.05.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies1
Human / animal / cellular1 / 0 / 0
Highest trial phasePreclinical
Years covered2007
Latest study9d ago
Publication history
20072007
Research funding
1,360 NIH projects · $26.0M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work
Community reports
Positive Neutral Negative
Records

Study register

1 rowOpen in the library →
StudyTypeYearSummary depth
The effect of tripeptide-copper complex on human hair growth in vitro.
FindingNot reported in abstract.
Human2007Full text read0.70